“TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure”

Activation of the atrial natriuretic signaling pathway is intrinsic to the pathological responses associated with a range of cardiovascular diseases that stress the heart, especially those involved in sustained cardiac pressure overload which induces hypertrophy and the pathological remodeling that...

Descripción completa

Detalles Bibliográficos
Autores principales: Horton, Jaime S., Shiraishi, Takuya, Alfulaij, Naghum, Small-Howard, Andrea L., Turner, Helen C., Kurokawa, Tatsuki, Mori, Yasuo, Stokes, Alexander J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298697/
https://www.ncbi.nlm.nih.gov/pubmed/30424709
http://dx.doi.org/10.1080/19336950.2018.1547611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298697/
https://www.ncbi.nlm.nih.gov/pubmed/30424709
http://dx.doi.org/10.1080/19336950.2018.1547611

Ejemplares similares